(株)ヘリオス
株価チャート
2026/08/21 更新株価トレンド
2026/08/21 更新株価・取引詳細
2026/08/21 更新株価
取引
アナリスト推奨 6 アナリスト
2026/08/01 更新決算日程
2026/08/01 更新過去の決算
| 日付 | EPS予想 | EPS実績 | サプライズ |
|---|---|---|---|
| 2026/05/13 | ¥-11.14 | ¥-27.65 | -148.2% |
| 2026/02/15 | ¥8.63 | ¥18.90 | +119.1% |
| 2025/11/12 | ¥6.37 | ¥7.54 | +18.4% |
| 2025/08/12 | ¥-6.79 | ¥-20.31 | -199.1% |
株主構成
2026/08/01 更新大株主
2026/08/01 更新| 機関名 | 保有比率 | 保有株数 | 変化 |
|---|---|---|---|
|
American Century ETF Trust-Avantis International Small Cap Equity ETF
|
200 | -95.45% |
財務パフォーマンス
2026/08/23 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥1億 | ¥1億 | ¥6億 | ¥1億 |
| 売上総利益 | ¥1億 | ¥1億 | ¥4億 | -¥1億 |
| 営業利益 | -¥52億 | -¥34億 | -¥28億 | -¥33億 |
| 経常利益 | -¥48億 | -¥29億 | -¥25億 | -¥19億 |
| 当期純利益 | -¥52億 | -¥38億 | -¥42億 | -¥22億 |
| EPS | -¥90.67 | -¥56.22 | -¥47.86 | -¥26.60 |
| 営業利益率 | -5,754.44% | -2,792.56% | -507.50% | -3,211.54% |
| 貸借対照表 | ||||
| 総資産 | ¥150億 | ¥152億 | ¥142億 | ¥171億 |
| 純資産 | ¥44億 | ¥39億 | ¥21億 | ¥49億 |
| 総負債 | ¥107億 | ¥113億 | ¥121億 | ¥122億 |
| 現金 | ¥72億 | ¥67億 | ¥37億 | ¥57億 |
| 有利子負債 | ¥71億 | ¥45億 | ¥27億 | ¥26億 |
| 自己資本比率 | 29.15% | 25.44% | 14.54% | 28.67% |
| D/Eレシオ | 1.63 | 1.18 | 1.29 | 0.53 |
| キャッシュフロー | ||||
| 営業CF | -¥46億 | -¥28億 | -¥18億 | -¥32億 |
| 投資CF | -¥9億 | -¥11億 | -¥14億 | -¥11億 |
| 財務CF | -¥25億 | ¥33億 | ¥1億 | ¥63億 |
| フリーCF | -¥49億 | -¥29億 | -¥21億 | -¥33億 |
| 効率性 | ||||
| ROE | -117.96% | -99.14% | -205.28% | -45.34% |
| ROA | -34.38% | -25.23% | -29.84% | -13.00% |
最新IR情報
最新ニュース (5件)
-
アナリスト平均評価: none
平均目標株価: ¥780
評価スコア: 1.50 (6人のアナリストによる評価)
※1=強い買い推奨、5=強い売り推奨
企業情報
会社概要
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.
